American Gene Technologies Reports Sustained HIV Reservoir Reduction in Phase 1 Trial of AGT103-T Cell Therapy
Key Insights
American Gene Technologies (search) presented Phase 1 clinical data showing AGT103-T cell therapy significantly reduced intact HIV proviral DNA (search) in all five evaluable patients at IAS 2025.
One patient's HIV (search) reservoir dropped from approximately 1,664 copies per million CD4+ T cells (search) to undetectable levels by Day 500, with suppression maintained for over two years.
The autologous T cell therapy selectively targeted replication-competent HIV (search) reservoirs while leaving defective proviral DNA stable, representing a potential breakthrough toward functional HIV cure.
American Gene Technologies (search) (AGT) announced compelling clinical results from its HIV (search) functional cure program at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda. The late-breaker presentation revealed that AGT103-T, an autologous T cell therapy, achieved sustained reductions in intact HIV proviral DNA (search) across all evaluable patients in its Phase 1 trial.
Significant Reservoir Reduction Observed
All five evaluable participants demonstrated significant decreases in intact HIV proviral DNA (search) in blood following AGT103-T treatment. The therapy utilizes a novel, modified Intact Proviral HIV (search) DNA Assay (IPDA) capable of distinguishing vector from viral sequences to measure treatment effects on the HIV reservoir.
The most striking result involved one subject whose reservoir dropped from approximately 1,664 copies per million CD4+ T cells (search) to undetectable levels by Day 500. This suppression has been sustained for over two years, representing an unprecedented level of reservoir depletion in HIV (search) cure research.
"These data provide early evidence that AGT103-T may directly reduce the replication-competent HIV (search) reservoir, a crucial step toward achieving a functional cure," said Jeff Galvin, CEO of American Gene Technologies (search). "The results support our belief that genetically modified autologous T cell therapy has the potential to transform HIV treatment paradigms."
Selective Impact on Replication-Competent Virus
The clinical data revealed that AGT103-T selectively targeted the replication-competent HIV (search) reservoir while leaving defective proviral DNA stable. This selective impact underscores the therapy's precision in addressing the specific viral components capable of replication, which represent the primary obstacle to achieving viral eradication or long-term remission without antiretroviral therapy.
Analytical treatment interruptions (ATI) provided additional insights into the immune system's enhanced ability to control viral rebound following AGT103-T infusion, suggesting improved immune control mechanisms.
Novel Therapeutic Approach
AGT103-T represents a first-in-class cell and gene therapy platform that genetically modifies a patient's own T cells to resist HIV (search) infection and enhance immune control. The treatment is administered as a single infusion and targets latent reservoirs, addressing a key challenge in HIV cure research.
"While still preliminary, these clinical outcomes are promising signs that an HIV (search) cure is within reach," said Dr. Wm David Hardy, AGT Scientific Advisory Board member and veteran HIV researcher. "The ability to establish viral control and, as these data demonstrate in an unprecedented manner, deplete the intact proviral reservoir holds exciting promise for the field."
Future Development Plans
AGT plans to initiate additional trials in 2026 to validate these findings in larger patient cohorts and refine analytical treatment interruption timing and monitoring strategies. The company is actively exploring strategic partnerships to accelerate development and expand access to this novel therapeutic approach.
The Phase 1 results represent a significant milestone in AGT's mission to deliver a durable, immune-based solution to HIV (search), potentially reducing or eliminating the need for lifelong antiretroviral therapy in treated patients.